2020年AL型淀粉样变性的管理
本文综述了AL型淀粉样变性的管理策略。该病由小B细胞克隆产生单克隆轻链导致器官毒性和淀粉样纤维沉积,器官受累决定临床表现但症状常晚期才被识别。治疗靶向潜在克隆并需风险适应,自体干细胞移植可用于约五分之一患者,硼替佐米是主要治疗骨架,达雷妥尤单抗联合硼替佐米正成为新标准。
要点
- 对已知单克隆丙种球蛋白病患者应筛查淀粉样器官功能障碍以实现症状前诊断。
- 治疗应风险适应,目标是早期和深度血液学缓解及长期器官缓解。
- 达雷妥尤单抗联合硼替佐米正成为AL型淀粉样变性新标准治疗。
核心结论
- AL型淀粉样变性治疗应靶向潜在克隆并风险适应,目标是早期深度血液学缓解和长期器官缓解。
研究设计与样本
- 本文为综述,总结AL型淀粉样变性的管理策略。
主要发现
- 约五分之一患者可考虑 upfront 或硼替佐米为基础 conditioning 后行自体干细胞移植。
- 硼替佐米可提高移植后缓解深度,且是不可移植患者的治疗骨架。
- 达雷妥尤单抗联合硼替佐米正成为AL型淀粉样变性新标准治疗。
- 复发/难治患者通常用免疫调节药物,达雷妥尤单抗也是有效选择。
关键数值与推荐
- 组织分型需在转诊中心用适当技术确认AL型淀粉样变性。
- 密切监测血液学缓解对将无应答者转为挽救治疗至关重要。
临床怎么用
- 对已知单克隆丙种球蛋白病患者筛查淀粉样器官功能障碍和损伤。
- 治疗应风险适应,快速给予患者可安全耐受的最有效治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. Organ involvement determines the clinical manifestations, but symptoms are usually recognized late. Patients with disease diagnosed at advanced stages, particularly when heart involvement is present, are at high risk of death within a few months. However, symptoms are always preceded by a detectable monoclonal gammopathy and by elevated biomarkers of organ involvement, and hematologists can screen subjects who have known monoclonal gammopathy for amyloid organ dysfunction and damage, allowing for a presymptomatic diagnosis. Discriminating patients with other forms of amyloidosis is difficult but necessary, and tissue typing with adequate technology available at referral centers, is mandatory to confirm AL amyloidosis. Treatment targets the underlying clone and should be risk adapted to rapidly administer the most effective therapy patients can safely tolerate. In approximately one-fifth of patients, autologous stem cell transplantation can be considered up front or after bortezomib-based conditioning. Bortezomib can improve the depth of response after transplantation and is the backbone of treatment of patients who are not eligible for transplantation. The daratumumab+bortezomib combination is emerging as a novel standard of care in AL amyloidosis. Treatment should be aimed at achieving early and profound hematologic response and organ response in the long term. Close monitoring of hematologic response is vital to shifting nonresponders to rescue treatments. Patients with relapsed/refractory disease are generally treated with immune-modulatory drugs, but daratumumab is also an effective option.
引用
- Palladini G, Milani P, Merlini G, et al. Management of AL amyloidosis in 2020. Blood. 2020. PMID: 33270858. doi:10.1182/blood.2020006913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。